Get the Stockscreener App
9.91
7.25%
0.67
After Hours:
9.94
0.03
+0.30%
Mersana Therapeutics Inc stock is traded at $9.91, with a volume of 183.82K.
It is up +7.25% in the last 24 hours and up +38.80% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$9.24
Open:
$9.28
24h Volume:
183.82K
Relative Volume:
2.12
Market Cap:
$49.46M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-1.2363
EPS:
-8.0157
Net Cash Flow:
$-79.76M
1W Performance:
+20.85%
1M Performance:
+38.80%
6M Performance:
+27.50%
1Y Performance:
-79.88%
1-Day Range:
$9.24
$10.32
1-Week Range:
$7.8275
$10.32
52-Week Range:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
9.91 | 46.11M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Why Mersana Therapeutics Inc. is moving todayJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Is Mersana Therapeutics Inc. stock ready for a breakoutTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com
Will Mersana Therapeutics Inc. stock beat EPS estimatesJuly 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com
Risk adjusted return profile for Mersana Therapeutics Inc. analyzedJuly 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
How to track smart money flows in Mersana Therapeutics Inc.2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Mersana Therapeutics Inc. (0M4) stock supported by free cash flow2025 Top Decliners & AI Driven Price Predictions - newser.com
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - MSN
Does Mersana Therapeutics Inc. fit your quant trading modelFed Meeting & Safe Entry Zone Tips - newser.com
Relative strength of Mersana Therapeutics Inc. in sector analysis2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Mersana Therapeutics (NASDAQ:MRSN) Stock Price Down 3.9% – Should You Sell? - Defense World
What MACD and RSI say about Mersana Therapeutics Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Why Mersana Therapeutics Inc. (0M4) stock attracts HNW investors2025 Pullback Review & Expert Curated Trade Ideas - newser.com
What valuation multiples suggest for Mersana Therapeutics Inc. stockJobs Report & Verified Momentum Stock Ideas - newser.com
What MACD signals say about Mersana Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Is Mersana Therapeutics Inc. stock bottoming outMarket Growth Report & Stepwise Trade Signal Implementation - newser.com
Is this a good reentry point in Mersana Therapeutics Inc.Short Setup & Daily Risk Controlled Trade Plans - newser.com
What drives Mersana Therapeutics Inc stock pricePrice Volatility Patterns & Build Winning Strategies With Zero Cost - earlytimes.in
How resilient is Mersana Therapeutics Inc. stock in market downturns2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Pattern recognition hints at Mersana Therapeutics Inc. upsideJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Is Mersana Therapeutics Inc a good long term investment - earlytimes.in
How Mersana Therapeutics Inc. stock compares to industry benchmarks2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Will a bounce in Mersana Therapeutics Inc. offer an exitEarnings Beat & AI Enhanced Execution Alerts - newser.com
How to use Fibonacci retracement on Mersana Therapeutics Inc.Breakout Watch & Comprehensive Market Scan Reports - newser.com
What technical models suggest about Mersana Therapeutics Inc.’s comebackJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
Published on: 2025-10-03 01:27:08 - newser.com
Published on: 2025-10-02 20:29:11 - newser.com
Applying Wyckoff theory to Mersana Therapeutics Inc. stock2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Mersana Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Fast Profit Investment Ideas - earlytimes.in
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mersana Therapeutics Inc Stock (MRSN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | President, CEO |
Sep 12 '25 |
Sale |
7.31 |
2,012 |
14,708 |
9,572 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
8,685 |
0 |
61,073 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):